AFCRO 2026 — OCTOPUS Study — mNSCLC BRAF V600E mutated
AFCRO 2026 competitive presentation — deployment of the TweenMe data pipeline on the OCTOPUS study (mNSCLC BRAF V600E mutated).
The OCTOPUS study is an ambispective RWE observational study involving 184 non-small cell lung cancer patients carrying the BRAF V600E mutation, from 5 European countries. Median follow-up of 16.7 months against an expected OS of 47.6 months (PHAROS). The rarity of the mutation and high censoring rates make robust survival modelling impossible using classical statistical methods.
The pipeline comprises five stages: CDISC ETL (59 SAS datasets, 37 SDTM domains, 11 selected), patient vectorisation (184 histories, 299 features), synthetic generation (Ontology Modeler + Smart Data Fertilizer + Bakery), multi-criteria validation, and survival modelling with counterfactual simulator.
The generic baseline (Synthetic Data Vault: CopulaGAN, CT-GAN, TVAE) fails on OS (log-rank p=0.004). The TweenMe pipeline produces curves statistically indistinguishable from real curves (OS p=0.911, PFS p=0.952) on a cohort scaled from 184 to 10,000 patients. The TSTR score (Train on Synthetic, Test on Real) reaches 95.2%.
Fine & Gray competing risks models, 5 endpoints per treatment sequence, individual simulation across all treatment combinations available in OCTOPUS. Opening towards a first indirect comparison of dabrafenib+trametinib vs. encorafenib+binimetinib on a real European population.
Selected in the top 5% of posters submitted to ISPOR 2026.